Uncommon Vasculopathies: Diagnosis and Endovascular Management

Wednesday, March 8, 2023

8:30 AM – 10:00 AM

Location:Phoenix Convention Center, 227ABC

CE: 1.5 Credits

Coordinator(s)

Amar Mukund, MBBS, MD

Professor and Program Director (PDCC in IR)
Institute of Liver and Biliary Sciences

Disclosure(s): BD Bard: Speaking and Teaching (Terminated); Boston Scientific: Speaking and Teaching (Ongoing)
Sanjeeva Kalva, MD, FSIR, FCIRSE, FACR (he/him/his)

Professor
Massachusetts General Hospital

Disclosure(s): BD Bard: Consultant (Ongoing); Biogen Inc, Clover Health Investments Corp, Inovio Pharmaceuticals, Moderna Inc, Pfizer Inc, Novavax Inc, Orphazyme, Cassava Sciences Inc, Vivos Therapeutics Inc, Ardelyx Inc, Althea Health, Sarepta Therapeutics, Clover Health Investments Corp, CureV: Ownership Interest (Ongoing), Stocks (Ongoing); Boston Scientific Corp: Consultant (Ongoing); Canon Medical: Consultant (Ongoing), Speaking and Teaching (Ongoing); Covidien/Medtronic: Consultant (Ongoing); Instylla, Inc.: Consultant (Ongoing); Okami Medical: Consultant (Ongoing); Penumbra Inc.: Consultant (Terminated), Speaking and Teaching (Terminated); Sirtex Medical: Consultant (Ongoing); Varian: Consultant (Ongoing)

Disclosure(s):

Amar Mukund, MBBS, MD: BD Bard: Speaking and Teaching (Terminated); Boston Scientific: Speaking and Teaching (Ongoing)

Sanjeeva Kalva, MD, FSIR, FCIRSE, FACR: BD Bard: Consultant (Ongoing); Biogen Inc, Clover Health Investments Corp, Inovio Pharmaceuticals, Moderna Inc, Pfizer Inc, Novavax Inc, Orphazyme, Cassava Sciences Inc, Vivos Therapeutics Inc, Ardelyx Inc, Althea Health, Sarepta Therapeutics, Clover Health Investments Corp, CureV: Ownership Interest (Ongoing), Stocks (Ongoing); Boston Scientific Corp: Consultant (Ongoing); Canon Medical: Consultant (Ongoing), Speaking and Teaching (Ongoing); Covidien/Medtronic: Consultant (Ongoing); Instylla, Inc.: Consultant (Ongoing); Okami Medical: Consultant (Ongoing); Penumbra Inc.: Consultant (Terminated), Speaking and Teaching (Terminated); Sirtex Medical: Consultant (Ongoing); Varian: Consultant (Ongoing)

This session will discuss the current role of imaging and endovascular therapy in the management of relatively less common inflammatory and non-inflammatory vasculopathies. Including Takayasu’s Arteritis, Thromboangitis Obliterans, Budd Chiari Syndrome, Segmental Arterial Mediolysis, Fibromuscular Dysplasia and Congenital Vascular Disorders (Marfan, Ehler Danlos, Loey Dietz)

Learning Objectives:

Upon completion, participant will be able to understand the clinical work up of patients suspected of inflammatory vasculopathies
Upon completion, participant will be able to understand the pathophysiology and the role of imaging in the work up various vasculopathies
Upon completion, participant will be able to understand the indications and role of endovascular therapy for treatment of various vasculopathies

Presentations:

8:30 AM – 8:43 AM

Takayasu's Arteritis
Speaker: Gireesh Warawdekar, MBBS, DMRE, FSIR – Lilavati Hospital
8:43 AM – 8:56 AM

Thromboangitis Obliterans
Speaker: Gireesh Warawdekar, MBBS, DMRE, FSIR – Lilavati Hospital
8:56 AM – 9:09 AM

Budd Chiari Syndrome
Speaker: Amar Mukund, MBBS, MD – Institute of Liver and Biliary Sciences
9:09 AM – 9:22 AM

Segmental Arterial Mediolysis
Speaker: Sanjeeva Kalva, MD, FSIR, FCIRSE, FACR (he/him/his) – Massachusetts General Hospital
9:22 AM – 9:35 AM

Fibromuscular Dysplasia
Speaker: Swatee Halbe, MBBS, MD – Apollo Speciality Hospitals
9:35 AM – 9:48 AM

Congenital Vascular Disorders (Marfan, Ehler Danlos, Loey Dietz)
Speaker: Michael D. Dake, MD (he/him/his) – University of Arizona
9:48 AM – 10:00 AM

Q & A
Speaker: Michael D. Dake, MD (he/him/his) – University of Arizona